Flare Therapeutics

Our team ‘brings it’ every day for one mission: to conquer transcription factors and create cutting-edge medicines. Flare Therapeutics is lighting up new frontiers in biotech by tackling transcription factors – an elusive protein class long considered “undruggable.” Leveraging our proteomic and mass spectrometry platform, proprietary electrophilic compound library and deep expertise, we are unlocking the potential of these critical proteins to address unmet needs in oncology and beyond. Our lead program, FX-909, is a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that is currently in a Phase I study. We have also advanced a second program with a differentiated mechanism for prostate cancer entering the Investigational New Drug (IND)-enabling stage, alongside a pipeline of earlier-stage programs targeting transcription factors involved in oncology and other therapeutic areas.